FDA Issues Reminder on Risk for Serious Fungal Infections With TNF-alpha Blockers, Including Simponi
May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...
Background. Psoriasis is a chronic, potentially debilitating inflammatory skin disorder associated with erosive arthritis and an increased risk for cardiovascular disease. [1] Management strategies ...
NEW YORK (Reuters Health) - Three available drugs that belong to the newest class of drugs for treating rheumatoid arthritis -- the tumor necrosis factor (TNF)-alpha blockers -- are equally effective ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and ...
WASHINGTON (Reuters) - U.S. health regulators have received more reports of rare blood cancer in young patients taking a class of anti-inflammatory drugs used to treat digestive disorders. The drugs, ...
REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) and Alvotech (ALVO), today announced the ...
The diagnostics advisory committee considered evidence on enzyme-linked immunosorbent assay (ELISA) tests (Promonitor, IDKmonitor, LISA‑TRACKER, RIDASCREEN, MabTrack, and tests used by Sanquin ...
BALTIMORE--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNFA” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel oral therapies for autoimmune ...
A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback